2026年1月20日 ， 软件型肺部影像公司 4DMedical 宣布，已通过新一轮机构配售完成 超过 1 亿美元（约 1.5 亿澳元） 融资。本轮资金将主要用于加速其核心 产品 CT:VQ™ 在美国市场的规模化部署，并显著提升研发投入，以巩固公司在软件化肺功能影像领域的技术优势。 这是 4DMedical 在美国业务推进过程中的一笔关键融资。公司表示，在获得新机构资金支持后，其将进一步推动已获 FDA 批准的 CT:VQ 软件在美国医院体系中 的落地，并围绕真实临床场景扩大使用规模。 融资完成后，4DMedical 披露其 备考口径下的现金规模已超过 1.3 亿美元（约 2 亿澳元） ，将为其美国扩张战略和不断增长的装机基础提供持续支撑。 # CT:VQ 是什么：让常规 CT 具备肺功能评估能力 CT:VQ 是 4DMedical 推出的核心产品，也是其本轮融资的技术基础。这是一款 基于常规胸部 CT 的肺部通气–灌注（Ventilation–Perfusion, V/Q）功能影像软 件 ，采用 SaaS 模式交付。 与传统依赖核医学检查或增强扫描的 V/Q 成像不同，CT:VQ 以 非增强胸部 CT 数据 ...

Funding will scale hospital deployments for groundbreaking CT:VQâ"¢ imaging product, strongly advance R&D, support early adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and more LOS ANGELES and MELBOURNE, Australia, Jan. 26, 2026 /PRNewswire/ -- 4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its c ...

Core Insights - 4DMedical has received FDA 510(k) clearance for CT:VQ™, the first non-contrast ventilation–perfusion imaging solution, and Medicare has confirmed reimbursement for this technology under Category III CPT codes, enhancing access to this imaging method nationwide [1][4]. Company Overview - 4DMedical is a global medical technology company focused on transforming respiratory care through advanced imaging and artificial intelligence, with patented technologies that enable quantitative ventilation and perfusion analysis from non-contrast chest CT scans [6]. Technology and Implementation - CT:VQ converts standard non-contrast chest CTs into quantitative lobar ventilation and perfusion maps, integrating seamlessly with existing radiology workflows and utilizing the installed base of approximately 14,500 CT scanners in the U.S. [3][4]. - The technology allows hospitals to perform high-resolution ventilation–perfusion studies without the need for new hardware or complex workflows, making it accessible to facilities without nuclear medicine capabilities [4]. Clinical Validation and Partnerships - More than one million nuclear V/Q scans are performed annually in the U.S., and 4DMedical's CT:VQ has undergone clinical validation through quantitative performance testing against SPECT and real-world studies across various lung conditions [5]. - Early clinical partners include Stanford University and Brooke Army Medical Center, which have presented initial findings at the 2025 American Thoracic Society meeting [5].